Proxy Votes Now

Home › Activist investors › Two Seas Capital LP

Two Seas Capital LP

Campaign activist. Positions and campaigns from Two Seas Capital LP’s SEC filings. Updated November 20, 2026.

Filer entities
Two Seas Capital LP
SEC CIK
1823138 (Two Seas Capital LP)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Oct 6, 2026: 32 US-listed positions reported; 15 of 1% or more of a company without a 13D are listed below.
17current positions
13new or changed in 90 days
0active campaigns
1campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (17)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
USA TODAY Co., Inc. 9.81%14,504,707 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 Feb 18, 2025 Increased Oct 6, 2026 ▲ 0.23 pts Increased 13F: none stated
Nektar Therapeutics 9.80%3,345,978 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 7, 2026 Feb 11, 2026 Increased Oct 6, 2026 ▲ 0.74 pts Increased 13F: none stated
Sable Offshore Corp. 8.91%17,101,876 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 7, 2026 Feb 18, 2025 Increased Oct 6, 2026 ▲ 4.55 pts Increased 13F: none stated
Calumet, Inc. 6.07%5,280,659 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Mar 31, 2026 Nov 14, 2024 Decreased Oct 6, 2026 ▼ 1.54 pts Decreased 13F: none stated
Arbutus Biopharma Corporation 4.12%8,143,994 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 10, 2026 Feb 14, 2022 Decreased Oct 6, 2026 ▼ 5.54 pts Decreased 13F: none stated
Quantum Corp. 3.78%1,490,992 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 6, 2026 Aug 12, 2026 Decreased Oct 6, 2026 ▼ 2.54 pts Decreased 13F: none stated
Core Scientific, Inc. 3.64%11,739,574 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 May 15, 2024 Increased Oct 6, 2026 ▲ 0.74 pts Increased 13F: none stated
STAAR Surgical Company 2.60%1,304,957 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2026 Increased Oct 6, 2026 ▲ 0.48 pts Increased 13F: none stated
Immunovant Inc. 2.23%4,612,692 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 3, 2026 Nov 14, 2023 Increased Oct 6, 2026 ▲ 0.71 pts Increased 13F: none stated
Sotera Health Company 2.14%6,111,053 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Oct 27, 2026 May 15, 2024 Increased Oct 6, 2026 ▲ 0.09 pts Increased 13F: none stated
uniQure N.V. 1.89%1,324,022 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 May 15, 2026 Decreased Oct 6, 2026 ▼ 0.19 pts Decreased 13F: none stated
Talen Energy Corporation 1.23%535,493 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 3, 2026 Aug 14, 2024 Increased Oct 6, 2026 ▲ 0.17 pts Increased 13F: none stated
Roivant Sciences Ltd. 1.01%7,325,356 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Jul 31, 2026 Feb 14, 2022 Decreased Oct 6, 2026 ▼ 0.16 pts Decreased 13F: none stated
Odyssey Marine Exploration Inc 10.0%5,857,448 shares Schedule 13D, filed Apr 13, 2026 Apr 13, 2026 — — — Seeks changes or engagement
Core Scientific, Inc. 6.3%19,122,842 shares Schedule 13D, filed Aug 8, 2025 Aug 8, 2025 — — — Seeks changes or engagement
Pavmed Inc. 5.77%461,539 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 13, 2026 May 15, 2026 — 0.00 pts — 13F: none stated
Lucid Diagnostics Inc. 2.95%6,000,000 shares 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 10, 2026 Nov 14, 2025 — 0.00 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Odyssey Marine Exploration Inc · Seeks changes or engagement

“…securities because they believed that such securities, when purchased, represented an attractive investment opportunity. On April 8, 2026, the Issuer, Oceanus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer ("Merger Sub"), and American Ocean Minerals Corporation, a Delaware corporation ("AOM,") entered into an Agreement and Plan of Merger (the "Merger Agreement") pursuant to which Merger Sub will merge with and into AOM,…”

Item 4 in the Schedule 13D filed Apr 13, 2026.

Core Scientific, Inc. · Seeks changes or engagement

“…purchased, represented an attractive investment opportunity. On July 7, 2025, the Issuer, CoreWeave, Inc., a Delaware corporation ("CoreWeave"), and Miami Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of CoreWeave ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides, upon the terms and subject to the conditions set forth therein, for a merger between Merger Sub…”

Item 4 in the Schedule 13D filed Aug 8, 2025.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (1)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Core Scientific, Inc.Board seatsGovernance changes Stake reported below 5% Apr 23, 2026 Aug 7, 2025 Proxy contest filed latest (26) —
Past positions (1)
CompanyLast stakeSourceOutcomeDate
Indivior PLC 5.0% Schedule 13D/A, filed Dec 23, 2025 Reported below 5% in a 13D/A Dec 23, 2025

How large managers voted in Two Seas Capital LP’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Settlement
Outcome of each campaign (1)
CompanyOutcomeDetailDateFirst filing
Core Scientific, Inc. Settlement agreement with the company Feb 19, 2026 Aug 7, 2025

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Core Scientific, Inc. · Feb 19, 2026 · Standstill

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Two Seas Capital LP’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Pavmed Inc. · Two Seas Capital LP first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
Aklog Lishan Schedule 13D Apr 9, 2026 5.1%
STAAR Surgical Company · Two Seas Capital LP first disclosed May 15, 2026 · 3 other filings
HolderFormDateStake
Madison Avenue International LP Schedule 13G Apr 20, 2026 5.8%
BlackRock, Inc. Schedule 13G Apr 24, 2026 13.1%
Point72 Asset Management, L.P. Schedule 13G May 12, 2026 5.2%
Nektar Therapeutics · Two Seas Capital LP first disclosed Feb 11, 2026 · 7 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Jan 30, 2026 5.0%
G1 Execution Services, LLC Schedule 13G Feb 13, 2026 4.0%
FMR LLC Schedule 13G Mar 6, 2026 11.1%
Two Seas Capital LP Schedule 13G Apr 17, 2026 6.8%
BVF Partners L P/Il Schedule 13G May 15, 2026 9.8%
BlackRock, Inc. Schedule 13G Jul 29, 2026 7.8%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.2%
Calumet, Inc. · Two Seas Capital LP first disclosed Nov 14, 2024 · 2 other filings
HolderFormDateStake
Heritage Group Schedule 13D Jul 11, 2024 17.2%
Wasserstein Debt Opportunities Management, L.P. Schedule 13D Feb 25, 2025 7.0%
Talen Energy Corporation · Two Seas Capital LP first disclosed Aug 14, 2024 · 4 other filings
HolderFormDateStake
Rubric Capital 13F Nov 13, 2024 8.3%
Sachem Head 13F Nov 14, 2024 2.7%
Carronade Capital 13F Nov 14, 2024 1.5%
The Vanguard Group Schedule 13G Jan 8, 2025 10.4%
Core Scientific, Inc. · Two Seas Capital LP first disclosed May 15, 2024 · 1 other filing
HolderFormDateStake
BlackRock Inc. Schedule 13D Nov 27, 2023 1.3%
Sotera Health Company · Two Seas Capital LP first disclosed May 15, 2024 · 1 other filing
HolderFormDateStake
Sachem Head 13F May 15, 2024 5.5%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.